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This study was designed to determine if a viable biodegradable three-dimensional fibroblast construct
(3DFC) patch implanted on the left ventricle after myocardial infarction (MI) improves left ventricular (LV)
function and blood flow. We ligated the left coronary artery of adult male Sprague-Dawley rats and im-
planted the 3DFC at the time of the infarct. Three weeks after MI, the 3DFC improved LV systolic function
by increasing (p < 0.05) ejection fraction (37 ± 3% to 62 ± 5%), increasing regional systolic displacement
of the infarcted wall (0.04 ± 0.02 to 0.11 ± 0.03 cm), and shifting the passive LV diastolic pressure volume
relationship toward the pressure axis. The 3FDC improved LV remodeling by decreasing (p < 0.05) LV end-
systolic and end-diastolic diameters with no change in LV systolic pressure. The 3DFC did not change LV
end-diastolic pressure (LV EDP; 25 ± 2 vs. 23 ± 2 mmHg) but the addition of captopril (2mg/L drinking
water) lowered (p < 0.05) LV EDP to 12.9 ± 2.5 mmHg and shifted the pressure–volume relationship toward
the pressure axis and decreased (p < 0.05) the LV operating end-diastolic volume from 0.49 ± 0.02 to 0.34 ±
0.03 ml. The 3DFC increased myocardial blood flow to the infarcted anterior wall after MI over threefold
(p < 0.05). This biodegradable 3DFC patch improves LV function and myocardial blood flow 3 weeks after
MI. This is a potentially new approach to cell-based therapy for heart failure after MI.
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INTRODUCTION Because of these drawbacks, we have developed a
different approach to cell-based therapy for heart failure;
we implant a matrix graft onto the infarcted heart toCell-based therapy with direct injection of cells into
the infarcted heart is currently being examined as a new provide a support structure for new blood vessel growth
(10). This matrix provides a more hospitable environ-treatment for heart failure. While a number of different
cell types have been shown to improve left ventricular ment for cell migration and growth into the damaged
left ventricle. In this report we provide data on a three-(LV) function in animal models of acute ischemic dam-
age, the results of direct cell injection into the heart in dimensional biodegradable dermal fibroblast construct
(3DFC) that is a matrix-embedded human construct ofclinical trials has been less dramatic (1,3,13,19,28–32,
36). In part, this appears to be because few of the trans- newborn dermal fibroblasts cultured in vitro onto a bio-
absorbable mesh to produce a living, metabolically ac-planted cells survive when injected into the infarcted
heart (2,14,21,34). While the explanation for this is not tive tissue that has the potential to increase new blood
vessel formation in vivo (15,16).clear, it may be that injecting cells directly into injured
myocardium or scar tissue is a problem because this Our hypothesis is that the 3DFC matrix or patch graft
will improve LV function and increase myocardial blooddamaged tissue is not a supportive milieu (i.e., scar tis-
sue has an inadequate blood supply with insufficient via- flow when implanted onto an infarcted heart. To test
this hypothesis, we created an anterior wall myocardialble tissue or matrix support for new cells to attach, sur-
vive, and grow). infarction (MI) by ligating the left coronary artery of
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rats, implanted the 3DFC patch at the time of surgery groups of rats: MI and captopril (2 g/L drinking water)
and MI + 3DFC patch and captopril (2 g/L drinking wa-and used solid-state micrormanometers to measure he-
modynamics, two-dimensional echocardiography to mea- ter) for 3 weeks.
sure LV regional wall motion, function, chamber size,
The 3DFC Patchimmunohistochemistry for microvessel density analysis,
and neutron-activated microspheres to measure myocar- The 3DFC patch is a cryopreserved human fibroblast-
derived tissue composed of fibroblasts, extracellular ma-dial blood flow. We treated a separate group of infarcted
rats with a combination of the 3DFC patch and captopril trix, and a bioabsorbable scaffold (15,16). Figure 1 is a
scanning electron micrograph of the 3DFC showing thatin order to simulate the clinically relevant situation
where a patient in heart failure after a MI is treated with the vicryl fibers are “tube-like” structures. The fibro-
blasts look like irregular structures with long append-an angiotensin converting enzyme inhibitor. The data
show that the 3DFC patch improves blood flow, regional ages that span from one vicryl fiber to another. The fi-
broblast cells are from a qualified cell bank, which haswall motion in the infarcted left ventricle, ejection frac-
tion (EF), and partially reverses maladaptive LV re- been extensively tested for animal viruses, retroviruses,
cell morphology, karology, isoenzymes, and tumor-modeling after MI. We do not see these results when a
nonviable patch alone is placed over the infarcted myo- genicity. Reagents used in the manufacture of the 3DFC
patch are tested and found free from viruses, retrovi-cardium. The addition of captopril to the 3DFC also
lowers LV end-diastolic pressure (LV EDP) and shifts ruses, endotoxins, and myocoplasma before use. One
piece of approximately 2 × 3 in. (5 × 7.5 cm) in size isthe LV pressure–volume relationship toward the pres-
sure axis. This study shows that placing a viable fibro- supplied frozen in a clear bag for a single-use applica-
tion. The patch remains frozen at −75 ± 10°C continu-blast matrix on the infarcted myocardium may be a new
approach to cell-based therapy for heart failure after ously until ready for use when it is placed in a sterile
bowl containing PBS (34–37°C). The patch is handleda MI.
gently by the edges to limit cellular damage and applied
MATERIALS AND METHODS to the heart within 60 min of being removed from its
Study Design and Treatment Groups container (Fig. 2). The 3DFC patch was provided by
Theregen, Inc. (San Francisco, CA).To test the efficacy of the 3DFC in the treatment of
To separate the effects of the cells from physical ef-heart failure after MI, we had five treatment groups: sham
fects of the vicryl we examined the effects of nonviable(N = 14); MI (N = 18); MI + 3DFC (N = 11); MI + 3DFC
3DFC. The nonviable 3DFC is the standard 3DFC that(nonviable) (N = 12); MI + 3DFC + captopril (N = 8).
is rendered nonviable by storage for 9 or more days at
Coronary Artery Ligation Experimental MI
−20°C. The nonviable 3DFC consists of the same biode-
gradable vicryl mesh with fibroblasts and extracellularHeart failure is created in rats using standard tech-
niques in our laboratory (8,9,12,24,26,33). In brief, rats matrix with matrix-bound growth factors and cytokines.
The fibroblasts are killed with the higher temperatureare anesthetized with ketamine and acepromazine and a
left thoracotomy performed. The heart is expressed from freeze phase (−20°C), leaving behind the standard extra-
cellular matrix (tissue) and matrix-bound proteins asthe thorax and a ligature placed around the proximal left
coronary artery. The heart is returned to the chest and well as the cellular debris. However, the nonviable
3DFC no longer contains viable, living cells.the thorax closed. The rats are maintained on standard
rat chow, water ad libitum, and pain medication postop- The viable 3DFC does not generate an immune re-
sponse. Developmental work on 3DFC includes experi-eratively. The experimental protocols are approved by
the animal use committees of the Southern Arizona VA ments in dogs treated with 3DFC showing no immune
response (Investigators’ brochure ITT-101, Theregen).Health Care System and the University of Arizona, guar-
anteeing that all animals have received human care in The work reported here is the first in an immune-compe-
tent animal showing that the benefits of the 3DFC arecompliance with the Guide for the Care and Use of Lab-
oratory Animals (www.nap.edu/catalog/5140.html). In- not related to the immune status of the recipient. The
low immunoginecity of allogeneic fibroblasts grown onfarcted rats undergoing this procedure have large MIs
averaging 40% of the ventricle (8,12). Myocardial in- a scaffold is thought to be due to the fact that the major-
ity of these fibroblasts show little induction of CD40farction is confirmed by hemodynamics (LV end-diastolic
pressure >16 mmHg) and presence of a scar. Prior to and HLA-DR in response to γ-interferon (17). The
3DFC patch is FDA approved for wound healing; it hasclosing the chest, the 3DFC patch is engrafted onto the
injured myocardium with the chest open as described been used in over 20,000 patients mostly as a skin graft
for diabetic foot ulcers with no untoward complications.below. The lungs are inflated, the chest closed, and the
rat allowed to recover. We treated two other separate There is no activation of the immune system in patients
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Figure 1. Scanning electron micrograph of the 3DFC patch. The vicryl fibers are “tube-like”
structures. The fibroblasts look like irregular structures with long appendages that span from one
vicryl fiber to another.
Figure 2. (A) Three-dimensional fibroblast culture (3DFC) prior to implantation; the suture in the middle of the patch is used to
attach the 3DFC to the left ventricle. (B) 3DFC at the time of implantation on the infarcted left ventricle. (C) 3DFC at 3 weeks
after myocardial infarction. Note that the 3DFC is well integrated and attached to the infarcted wall. (D) 3DFC in a perfused heart
preparation at 3 weeks after myocardial infarction. As note above, the 3DFC is well integrated into the infarcted wall and the suture
is easily visible.
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treated with this patch for diabetic foot ulcers, other skin ing M-mode through the anterior wall of the left ventri-
cle, the LV wall thickness is measured at diastole andrepair, and oropharyngeal palate repair.
systole; the difference in the thickness between the two
Hemodynamic Measurements measurements is the systolic displacement. This is a use-
ful measurement to quantify focal LV wall systolic func-We measure hemodynamics using methods reported
previously by our laboratory (9,10,24–26,33). In brief, tion.
rats are anesthetized with inactin (100 mg/kg IP injec-
tion) and placed on a specially equipped operating table Myocardial Perfusion
with a heating pad to maintain constant body tempera- We use neutron activated microspheres (BioPal Inc,
ture. Following endotracheal intubation and placement Worcester MA) to measure myocardial blood flow. The
on a rodent ventilator, a 2F solid state micromanometer isotopes are injected, a tissue sample obtained, and at a
tipped catheter with two pressure sensors (Millar) is in- later time activated with the emitted radiation measured
serted via the right femoral artery, with one sensor lo- with high-resolution detection equipment (7,18,27).
cated in the left ventricle and another in the ascending With this system, BioPal, Inc. provides the isotopes and
aorta. The pressure sensor is equilibrated in 37°C saline tissue containers. Three separate isotopes (lutetium, gold,
prior to obtaining baseline pressure measurements. After and samarium) are injected in each rat: one at baseline
a period of stabilization, LV and aortic pressures, and prior to coronary ligation, one immediately after liga-
heart rate are recorded and digitized at a rate of 1000 tion, and one at the endpoint of the study. Because dif-
Hz using a PC equipped with an analog-digital converter ferent rats are used for each group we are able to obtain
and customized software. From these data, LV dP/dt is end point data after different treatments (MI at 3 weeks,
calculated. MI at 3 weeks + 3DFC). For each measurement 750,000
nonradioactive elementally labeled 15-µm microspheresLV Pressure–Volume Relationships (V = 300 µl) from Biopal, Inc. are injected into the left
The LV pressure–volume relationship is measured as ventricle transapically with a 1-cc syringe and 27-gauge
outlined in our previous work (8,12). In brief, the heart needle. At the terminal study point, the tissues are har-
is arrested with potassium chloride, and a catheter con- vested, oven dried, and collected for analysis. At the
sisting of PE-90 tubing with telescoped PE-10 tubing time of microsphere injection we perform a transthoracic
inside is inserted into the LV via the aortic root. One echocardiogram to measure stroke volume. By knowing
end of the double-lumen LV catheter is connected to a the heart rate, we calculate cardiac output as stroke vol-
volume infusion pump (Harvard Apparatus) while the ume × heart rate. Assuming 4% of the cardiac output
other end is connected to a pressure transducer zeroed perfuses the coronary arteries (27), we know the total
at the level of the heart. The right ventricle is partially myocardial blood flow; the number of microspheres de-
incised to prevent loading on the LV. The LV is filled posited in the anterior wall is percentage of blood flow(1.0 ml/min) to 60–100 mmHg and unfilled while pres- down the left coronary artery to the anterior wall at each
sure is recorded onto a physiologic recorder (Gould). time point.
Ischemic time is limited to 10 min. Volume infused is a
function of filling rate. Histopathology
Hearts were formalin fixed (10%) prior to paraffinEchocardiography
embedding. HIER antigen retrieval of 3-µm-thick sec-We perform closed chest transthoracic echocardiogra-
tions was performed in citrate-based Diva buffer (pHphy at baseline prior to the MI, immediately after MI,
6.2) for 1 min at 125°C using a “Decloaker” pressureand at 3 weeks after MI using methods previously devel-
cooker (Biocare Medical Concord, CA). We used singleoped in our laboratory (33). We use a Vingmed, Vivid
immunohistochemical staining for anti-rabbit factor VIII7 system echo machine (GE Ultrasound) with EchoPac (Dako) (1:1000) to perform histological analysis of mi-(GE Ultrasound) programming software with a 10 MHz
crovessel density.multiplane transducer with views in the parasternal short
axis and long axis, to specifically evaluate the anterior,
Vessel Densitylateral, anterolateral, inferior, and posterior walls. Two-
dimensional (2D) and M-mode measurements of myo- We defined vessel density by light microscopy at 40×
magnification. The number of cross section vessels percardial wall thickness and LV dimensions are obtained
throughout the cardiac cycle and are used for calculation field was counted by two persons blinded to treatment.
Average measurements from six different fields were re-of systolic displacement of the anterior wall, ejection
fraction, and regional fractional shortening. Systolic dis- corded for each value. Knowing the area of the optical
field, data are reported as number of vessels/µm2.placement is a measure of focal LV wall thickening. Us-
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Statistical Analysis 2.3 ± 3.7 to 9.1 ± 1.9 mmHg/ml/min; compared to acute
MI, vascular resistance in chronic heart failure was un-Data are expressed as mean ± SE. For the physiologic
changed at 7.7 ± 0.92 mmHg/ml/min. The 3DFC de-and echocardiographic measurements, the effects of the
creased (p < 0.05) vascular resistance to 3.9 ± 0.86; the3DFC were determined by using two-way analysis of
addition of captopril further decreased (p < 0.05) vascu-variance followed by the Student t-test. The value of p <
lar resistance to 0.41 ± 0.03 mmHg/ml/min.0.05 was accepted as significant. The authors had full
access to the data and take responsibility for its integrity.
Echocardiographic Changes in LV FunctionAll authors have read and agree to the manuscript as
and PV Loopswritten.
The data on global and regional changes in LV func-RESULTS
tion are seen in Figures 3, 4, 5, and 6. There was a
In Vivo Hemodynamics decrease (p < 0.05) in LV EF (75 ± 4% to 37 ± 3%)
with the acute MI and a subsequent increase (p < 0.05)Rats with MI had a fourfold increase in left ventricu-
lar end diastolic pressure, a 22% reduction in LV sys- with the 3DFC patch (53 ± 4%). The EF did not in-
crease with the nonviable 3DFC (31 ± 2%); the additiontolic blood pressure, a 24% reduction in mean arterial
blood pressure, a 37% reduction in left ventricular dP/ of captopril to the 3DFC did not change the EF com-
pared to 3DFC alone (48 ± 3%). The changes in regionaldt, and a 21% prolongation of the time constant of LV
relaxation or tau (Table 1). The baseline data are consis- LV function, defined as systolic displacement calculated
from parasternal short axis M-mode echocardiography,tent with our previous reports using this model showing
that ligation of the left coronary artery results in a large were similar. With the coronary ligation, there was a
decrease (p < 0.05) in systolic displacement of the ante-anterior wall MI and heart failure with a decrease in
LV systolic function, an elevation of LV EDP, and a rior infarcted wall (0.15 ± 0.03 to 0.05 ± 0.02 cm) with
a return toward normal with the placement of the 3DFCprolongation of tau (8,9,12,24–26,33). The 3DFC low-
ered (p < 0.05) mean arterial pressure and increased patch (0.11 ± 0.04 cm). The nonviable 3DFC did not al-
ter EF or systolic displacement.(p < 0.05) peak developed pressure or PDP (126 ± 4 to
146 ± 8 mmHg). The LV end-diastolic diameter increased (p < 0.05)
from 4.6 ± 0.4 to 8.1 ± 0.3 mm and the LV end-systolic
Captopril Treatment diameter increased (p < 0.05) from 1.2 ± 0.2 to 4.1 ± 0.7
mm 3 weeks after MI (Fig. 5). The 3FDC patch de-Treatment with captopril after MI lowered (p < 0.05)
MAP, LV SP, and LV EDP; these changes are similar creased (p < 0.05) LV end-diastolic diameter to 6.6 ±
0.4 mm and end-systolic diameter to 1.8 ± 0.08 mm. Theto what we and other investigators have previously
shown (26). The addition of captopril in the 3DFC rats PV relationship shows dilatation of the ventricle with
the MI but no shift when the 3DFC patch was addedlowered LV EDP from 23 ± 2 to 13 ± 3 mmHg and PDP
from 146 ± 8 to 123 ± 5 mmHg (p < 0.05); all other he- (Fig. 6). The addition of captopril to the 3DFC shifted
the PV loop to the left toward the pressure axis and de-modynamic parameters were unchanged (Table 1). Vas-
cular resistance increased (p < 0.05) with acute MI from ceased the operating LV end-diastolic volume from 0.57 ±
Table 1. Hemodynamics for 3DFC Patch/Captopril After MI
MAP HR LV SP LVEDP LV dP/dt PDP Tau
(mmHg) (bpm) (mmHg) (mmHg) (mmHg/s) (mmHg) (ms)
Sham (N = 14) 106 ± 5 287 ± 15 124 ± 5 7 ± 1 7360 ± 379 192 ± 18 19.0 ± 1.3
MI (N = 18) 90 ± 2* 269 ± 13 103 ± 3* 25 ± 2* 4542 ± 215* 126 ± 4 24.2 ± 1.8*
MI + captopril (N = 11) 72 ± 3* 283 ± 15 88 ± 3†‡ 14 ± 2† 4398 ± 315* 118 ± 7* 21.8 ± 1.8*
MI + 3DFC (viable) (N = 11) 84 ± 3† 248 ± 10 100 ± 5* 23 ± 2*‡ 4242 ± 156* 146 ± 8†§ 29.7 ± 3.5*
MI + 3DFC (nonviable) (N = 12) 88 ± 4* 270 ± 7 102 ± 4* 24 ± 2* 4502 ± 179* 118 ± 4 26.0 ± 3.0*
MI + 3DFC (viable) + captopril (N = 8) 83 ± 4† 265 ± 23 100 ± 6* 13 ± 3† 4502 ± 179* 123 ± 5§ 25.8 ± 2.8*
Values are mean ± SE. MAP, mean arterial pressure; MI, myocardial infarction; LV, left ventricular; LV EDP, LV end-diastolic pressure; PDP,
peak developed pressure; Tau, time constant of LV relaxation; 2DFC, three-dimensional fibroblast construct.
*p < 0.05 versus sham.
†p < 0.05 versus sham and MI.
‡p < 0.05 versus MI + 3DFC/captopril.
§p < 0.05 versus sham and MI + 3DFC.
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Figure 3. Echocardiographic measured ejection fraction (EF) in sham, myocardial infarction (MI),
MI + 3DFC, MI + 3DFC/Cap (captopril), and MI + 3DFC/NV (nonviable). Note that the viable
3DFC increased the EF. The EF remained increased with the addition of captopril to the viable
3DFC; the nonviable 3DFC did not improve EF. Values are mean ± SE. Sham (N = 5); MI (N =
8); MI + 3DFC/cap (N = 10); MI + 3DFC (N = 14); MI + 3DFC (nonviable) (N = 5). *p < 0.05
sham versus all groups; **p < 0.05 MI and MI + 3DFC/NV versus MI + 3DFC/cap and MI +
3DFC.
Figure 4. Echocardiographic measured systolic displacement of the infarcted anterior wall in sham,
myocardial infarction (MI), and MI + 3DFC. Note that the 3DFC improved EF back toward the
normal value. Values are mean ± SE. Sham (N = 6); MI (N = 12); MI + 3DFC (N = 15); MI + NV
3DFC (N = 12). *p < 0.05 versus MI; **p < 0.05 versus MI.
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Figure 5. Echocardiographic measured LV end-diastolic and end-systolic diameters in sham, myo-
cardial infarction (MI), and MI + 3DFC. Note that both the LV end-diastolic diameter and end-
systolic diameters decrease with the 3 DFC. Values are mean ± SE. Sham (N=6); MI (N=12);
MI + 3DFC (N=15); MI + NV 3DFC, (N=12). *p < 0.05 versus sham; **p < 0.05 versus MI.
0.05 to 0.34 ± 0.03 ml (p < 0.05). The nonviable 3DFC DISCUSSION
did not alter end-diastolic or end-systolic diameter.
The important findings in this study are that this
Increased Blood Vessels and Myocardial Blood Flow three-dimensional biodegradable fibroblast patch in-
creases myocardial blood flow in the damaged region ofWith acute MI, there was an approximately 80% de-
crease in blood flow to the infarcted wall, which was the LV and increases systolic displacement in the ante-
rior infarcted wall after an acute MI. The 3DFC reversesnot altered at 3 weeks. With the 3DFC, the blood flow
increased to about 70% of baseline (Fig. 7). The increase maladaptive LV remodeling, by increasing EF and de-
creasing LV end-diastolic and end-systolic diameters.in blood flow was a result of new blood vessel formation
with the 3DFC (Figs. 8 and 9). The addition of captopril lowers LV end-diastolic pres-
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Figure 6. Pressure–volume (PV) loops in sham, myocardial infarction (MI), MI + 3DFC, and
MI + 3DFC/captopril. Note that the major shift in the PV loop was with the addition of captopril
where the operating LV end-diastolic volume decreased.
sures and decreases the operating LV end-diastolic vol- ing that at 1 year, bone marrow cell injection with a
higher percentage of CD34+ cells decreases reinfarctionsume. These data support our hypothesis that this viable
fibroblast patch provides a supporting structure for the and revascularization procedures with revascularizations
driving an improved composite end-point of revascu-damaged heart and may be an alternative to direct cell
injection for cell-based therapy for heart failure after MI. larizations, MI, and death (30). We believe that this gen-
eral lack of positive results with direct cell injection is
Cell-Based Therapy for Heart Failure due in part to the observation that most of these newly
injected cells do not survive chronically in the infarctedWhile the original animal data with cell-based ther-
apy for heart failure were very encouraging, the results heart and do not transdifferentiate into cardiac myocytes
(2,21,34). Investigators are now injecting cardiac stemfrom the most recent clinical trials with direct cell injec-
tion into the heart and/or coronary arteries have been cells into the heart in an attempt to obviate the need for
stem cells to transdifferentiate (23).disappointing. Clinical trials such as the BOOST,
TOPCARE, the IACT, the REPAIR-MI, the ASTAMI
Three-Dimensional Fibroblast PatchTrial, and a bone marrow transplant study from Belgium
of intracoronary delivery of autologous bone marrow Our hypothesis is that the lack of survival of new
cells directly injected into the heart is related, in part, tocells in patients after MI with PCI show only modest
improvement in LV function, mostly in patients with an inadequate blood supply and inadequate matrix sup-
port for the new cells. The injected cells are fragile, re-preserved EFs with some questions about delivery tech-
niques (1,3,13,19,23,28–32,36). The most positive re- sulting in cell aggregation due to lack of physical sup-
port for the cells to attach to the tissue extracellularsults are a subset analysis of the REPAIR-MI trial show-
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Figure 7. Anterior wall myocardial blood flow in sham (N = 11), at the time of acute myocardial
infarction (MI, N = 7), MI at 3 weeks (N = 4), and MI at 3 weeks with 3DFC (N = 4). Note that
the 3DFC improved blood flow in the infarcted wall. Values are mean ± SE; *p < 0.05 versus
baseline and MI (3w) + 3DFC.
matrix. This three-dimensional scaffold offers a poten- providing a new support structure for the damaged heart,
we also need to create a mature blood supply such thattial solution to the problem of an inadequate support
structure. While injection of passive materials has been new viable cardiac muscle can be organized in parallel
forming physical and neural connections that will con-proposed to improve EF potentially by decreasing wall
stress (11,35), the 3DFC provides a viable cell matrix duct electrical signals and create synchronized contrac-
tions. Investigators have proposed that the ideal scaffoldthat supports new blood vessel growth (15,16). This via-
ble cellular matrix is important because in addition to structure for the heart would consist mainly of highly
Figure 8 Vessel density defined by Factor VIII staining. Note the increase in vessel density in the
area with the 3DFC compared to the untreated myocardial infarction (MI). MI (N = 9), MI + 3DFC
(N = 8). Values are mean ± SE. *p < 0.05 versus MI.
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Figure 9. Histopathology sections of Factor VIII staining in MI + 3DFC (A–C) and MI alone (4× and 40×). Note the increased in
Factor VIII staining and vessel density with the 3DFC.
interconnected pores with a diameter of at least 200 µm, blood vessel growth has been documented previously in
SCID mice (15).the average size of a capillary, to permit blood vessel
penetration and cell interactions (5). Previous work using the 3DFC as a patch for the in-
farcted heart in SCID mice showed histological evidenceThe 3DFC is a viable construct composed of a matrix
embedded with human newborn dermal fibroblasts cul- of new blood vessel growth and improvements in global
LV function using a conductance catheter (16). Our datatured in vitro onto a bioabsorbable mesh to produce liv-
ing, metabolically active tissue (15,16) (see Figs. 1 and show increases in myocardial blood flow in the infarcted
heart, confirming that these blood vessels are functional2). As the fibroblasts proliferate across the mesh, they
secrete human dermal collagen, fibronectin, and glyco- and that they connect to the native myocardium. We
used echocardiography to document improvements insaminoglycans (GAGs), embedding themselves in a self-
produced dermal matrix. The fibroblast cells produce global and regional LV function. The improvements in
regional LV function are important because recent workangiogenic growth factors: vascular endothelial growth
factor (VEGF), hepatocyte growth factor (HGF), basic suggests that the injection of passive materials alone
may be enough to reduce wall stress and increase globalfibroblast growth factor (bFGF), and angiopoietin-1.
The construct is grown in medium supplemented with EF (35). In order to prove that cell-based therapy is af-
fecting more than a passive response, the point has beenserum and ascorbate; at harvest, the medium is replaced
with a 10% DMSO-based cryoprotectant, the tissue is made that it is necessary to be able to define regional
changes in the area of the infarcted myocardium (11).frozen and stored at −70°C. This cryopreservation and
rewarming technique has been extensively studied to en- We have done this using echocardiography to document
that the 3DFC increases systolic displacement of the in-sure viability of the patch. Although the mechanisms of
action of the 3DFC are not completely understood, new farcted regional anterior wall (Fig. 5). Although the
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mechanism of action of the 3DFC has not been com- a area of viable myocardium. This trial is designed to
determine if the 3DFC increases myocardial perfusionpletely delineated, the viable fibroblasts secrete a num-
ber of growth factors, thus providing a paracrine effect to an area that the surgeon could not graft. While in this
clinical study the 3DFC patch is placed with the chestto stimulate new blood vessel growth. The vicryl mesh
is biodegradable such that, with dissolution, the new open, two cases have been done with a minimally inva-
sive approach using a modified video-assisted thoras-blood vessel growth is in the previously damaged myo-
cardium. The most likely explanation for the improve- copic surgery VATS procedure. The second trial is in
patients getting a left ventricular assist device (LVAD).ments in regional systolic displacement of the anterior
wall is that the increases in myocardial blood flow in The 3DFC is applied at the time of LVAD placement
and, upon LVAD removal, histology is done on the areathe border zone results in recruitment of hibernating or
stunned cardiac myocytes. of 3DFC placement in order to examine for evidence of
angiogenesis.The fact that the 3DFC is viable with fibroblasts im-
planted on a mesh is important. There are data showing
that inert biodegradable patches are beneficial in treating Summary
heart failure. In our laboratory we have shown that an We report improvements in myocardial blood flow,
inert biodegradable collagen patch placed on the rat regional and global LV function, and partial reversal of
heart after a nontransmural MI improves LV function LV remodeling using a viable three-dimensional fibro-
and prevents adverse LV remodeling (10). There are blast patch implanted in rats at the time of an acute MI.
clinical trials with a collagen type 1 matrix seeded with This patch provides a support structure that allows cells
autologous bone marrow cells in patients undergoing to grow into the damaged heart and creates new blood
coronary artery bypass surgery (4). The best known im- vessel growth, resulting in improved blood flow. With
planted mechanical constraint device is the Acorn Corp the limited success of direct cell injection into the heart,
Cap device; it decreases LV size but does not cause con- the 3DFC represents a new approach to cell-based ther-
strictive physiology (22). There are no blood flow stud- apy for heart failure.
ies with the Acorn device. There is a recent report using
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